Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines

Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines

Advanced small cell lung cancer (SCLC) has a dismal prognosis. Modulation of the camptothecin topotecan, approved for second-line therapy, may improve response. Our recent finding of synergistic enhancement of the cytotoxic activity of camptothecin (CPT) by cyclin-dependent kinase 4 inhibitors is ex...

Full description

Bibliographic Details
Main Authors: Gerhard Hamilton, Lukas Klameth, Barbara Rath, Theresia Thalhammer
Format: Article
Language:English
Published: MDPI AG 2014-02-01
Series:Molecules
Subjects:
small cell lung cancer
camptothecin
topotecan
rubitecan
cyclin-dependent kinase inhibitor
PD0332991
roscovitine
olomoucine
chemoresistance
MTT assay
cell cycle
topoisomerase I
Online Access:http://www.mdpi.com/1420-3049/19/2/2077

Internet

http://www.mdpi.com/1420-3049/19/2/2077

Similar Items